Floriana Cremasco

As the field matures, developers are grappling with two persistent barriers: poor tumor penetration and a treatment landscape that is rapidly filling with combination options. This session brings together perspectives on where next-generation ADC design is heading, from tumor-activated and conditionally active constructs to novel target combinations such as PD-L1/VEGF ADCs positioned as alternatives to bispecifics, and asks what the competitive and combination landscape will look like as these approaches mature.

Learning Takeaways:

• Understand the emerging competitive landscape for ADC linker technology, including new protease-specific linkers, and what this means for differentiation against established assets.
• Explore practical strategies being developed to address poor tumor penetration, a barrier that continues to limit the efficacy of large molecule ADCs in solid tumors.
• Consider how novel dual-function constructs, such as a PD-L1/VEGF ADC, could offer a differentiated path compared to bispecific approaches, and what this signals for future combination strategy